Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate... Eur J Nucl Med Mol Imaging (2017) 44:1671–1678 DOI 10.1007/s00259-017-3756-7 ORIGINAL ARTICLE Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer 1 2 3 4 5 Yong Du & Ignasi Carrio & Giuseppe De Vincentis & Stefano Fanti & Harun Ilhan & 6 7 8 9 Caroline Mommsen & Egbert Nitzsche & Francis Sundram & Wouter Vogel & 1,10 11 Wim Oyen & Val Lewington Received: 2 June 2017 /Accepted: 7 June 2017 /Published online: 19 June 2017 The Author(s) 2017. This article is an open access publication Abstract UK) experienced in administering radium-223. The findings Purpose Radium Ra 223 dichloride (radium-223, Xofigo®) were collated and discussed at a meeting of experts from these is the first targeted alpha therapy for patients with castration- centres, during which key consensus recommendations were resistant prostate cancer and symptomatic bone metastases. defined. Radium-223 provides a new treatment option for this setting, Results The recommendations cover centre organization and but also necessitates a new treatment management approach. preparation; patient referral; radium-223 ordering, preparation We provide straightforward and practical recommendations and disposal; radium-223 treatment delivery/administration; for European nuclear medicine centres to optimize radium- and patient experience. Guidance includes structured coordi- 223 service provision. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Journal of Nuclear Medicine and Molecular Imaging Springer Journals

Loading next page...
 
/lp/springer_journal/practical-recommendations-for-radium-223-treatment-of-metastatic-s0dmggjaPU
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Nuclear Medicine; Imaging / Radiology; Orthopedics; Cardiology; Oncology
ISSN
1619-7070
eISSN
1619-7089
D.O.I.
10.1007/s00259-017-3756-7
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial